Oxandrolone and Primobolan Interaction: Avoid | Peptide Database

Join others researching Ezetimibe — share findings, ask questions, and learn from real experiences Ezetimibe is a selective cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the brush border of the small intestine, preventing dietary and biliary cholesterol from entering the bloodstream. Approved by the FDA in 2002, it occupies a unique niche among lipid-lowering agents by targeting intestinal cholesterol uptake rather than hepatic cholesterol synthesis. In the context of anabolic steroid use, ezetimibe has become a go-to ancillary compound for managing the dyslipidemia that accompanies many AAS cycles, particularly oral steroids like oxandrolone (Anavar) and stanozolol (Winstrol) that are notorious for crashing HDL cholesterol and elevating LDL. While statins remain the first-line treatment for hypercholesterolemia in the general population, ezetimibe is frequently used alone or stacked with a statin by steroid users seeking to mitigate cycle-induced lipid damage without adding yet another hepatotoxic compound to the mix. Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle. By blocking this transporter, ezetimibe reduces cholesterol delivery to the liver, which in turn upregulates hepatic LDL receptor expression to compensate for the reduced cholesterol supply. This upregulation increases LDL clearance from the bloodstream. The mechanism is entirely complementary to statins, which inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis. When the liver is deprived of cholesterol from both sources simultaneously, the LDL-lowering effect is significantly amplified. Ezetimibe undergoes glucuronidation in the intestinal wall and liver to form its active metabolite, ezetimibe-glucuronide, which is also pharmacologically active and participates in enterohepatic recirculation, contributing to the drug's prolonged duration of action.

Join others researching Ondansetron — share findings, ask questions, and learn from real experiences Ondansetron is a selective serotonin 5-HT3 receptor antagonist originally developed and FDA-approved for the prevention of nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. It works by blocking serotonin signaling in both the gut and the brain's chemoreceptor trigger zone, making it one of the most effective and widely prescribed anti-emetics available. In the performance-enhancement and peptide community, ondansetron has become an essential support compound for managing nausea caused by a range of commonly used agents. GLP-1 receptor agonists like semaglutide and tirzepatide are notorious for dose-dependent nausea, particularly during titration phases, and ondansetron is the go-to solution for keeping users compliant with their protocols. It is similarly relied upon for nausea triggered by HCG, nandrolone (Deca/NPP), pramipexole, and various oral compounds that cause gastric distress. The orally disintegrating tablet (ODT) formulation is especially popular because it dissolves on the tongue in seconds and does not require swallowing a pill while actively nauseated. Ondansetron exerts its anti-emetic effects through selective antagonism of serotonin 5-HT3 receptors. These receptors are concentrated in two key areas relevant to nausea: the vagal afferent nerve terminals in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) in the area postrema of the brainstem. When emetogenic stimuli (chemotherapy, medications, gut irritation) cause enterochromaffin cells in the gut to release large amounts of serotonin, this serotonin activates 5-HT3 receptors on vagal afferents, which transmit nausea signals to the brainstem vomiting center. Ondansetron blocks this signaling pathway at both the peripheral (gut) and central (CTZ) level. Unlike dopamine antagonists such as metoclopramide, ondansetron does not block D2 receptors and therefore does not cause extrapyramidal side effects or prolactin elevation, making it a much cleaner anti-emetic for long-term or repeated use. The drug is metabolized hepatically via CYP3A4 and CYP1A2 and is eliminated with a half-life of approximately 4 hours.